Australien - engelska - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - methotrexate, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; hydrochloric acid; water for injections - china: methotrexate has a broad spectrum of antineoplastic activity and may be used as a single agent or as part of a combined therapy programme. it is indicated for the following: ? antineoplastic therapy, single agent: breast cancer, gestational choriocarcinoma, chorioadenoma destruens or hydatidiform mole. ? antineoplastic therapy, combined treatment: acute leukaemias (particularly acute lymphoblastic). burkitt?s lymphoma, advanced stages (iii and iv, peter?s staging system) of lymphosarcoma and advanced mycosis fungoides. ? intrathecally: for meningeal metastases (using isotonic preparations only). ? high dose therapy: methotrexate may be used at high doses as a single agent or in combination with other chemotherapeutic agents to treat the following: osteogenic sarcoma, acute leukaemia, bronchogenic carcinoma or epidermoid cancer of the head and neck. ? psoriasis chemotherapy: methotrexate may be useful in the treatment of severe, recalcitrant, disabling psoriasis which has been shown to be unresponsive to conventional treatment.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - methotrexate, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - denmark: methotrexate is a cytotoxic drug used for antineoplastic chemotherapy and in certain nonmalignant conditions. oncological indications: methotrexate is indicated for the treatment of the following solid tumors and hematologic malignancies: ? choriocarcinoma (gestational trophoblastic neoplasm) ? chorioadenoma destruens ? hydatidiform mole ? acute lymphoblastic leukemia ? breast cancer ? cervical cancer ? ovarian carcinoma ? testicular carcinoma ? bladder cancer (locally advanced/metastic) ? epidermoid cancers (squamous cell carcinoma) of head and neck ? mycosis fungoides (cutaneous t cell lymphoma) ? lung cancer ? non-hodgkin?s lymphoma ? meningeal lymphoma ? histiocytic and lymphatic lymphoma, burkitt?s lymphoma ? osteosarcoma ? meningeal leukemia other diseases: ? psoriasis ? rheumatoid arthritis including polyarticular-course juvenile rheumatoid arthritis (jra)

Australien - engelska - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - methotrexate, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - spain: methotrexate is indicated for the treatment of various tumor diseases such as choriocarcinoma (development of a tumor directly associated with pregnancy), acute leukemia, breast cancer, head and neck cancer, urinary bladder cancer, osteogenic sarcoma (cancer of the bones) and malignant lymphomas. it is also used to prevent and treat meningeal leukemia (leukemia infiltration into the central nervous system). it is also used in the treatment of severe rheumatoid arthritis; in the treatment of juvenile idiopathic arthritis, psoriasis and psoriatic arthritis. it is also indicated for the prevention of graft-versus-host disease in allogeneic bone marrow transplantation.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - methotrexate, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - spain: methotrexate is indicated for the treatment of various tumor diseases such as choriocarcinoma (development of a tumor directly associated with pregnancy), acute leukemia, breast cancer, head and neck cancer, urinary bladder cancer, osteogenic sarcoma (cancer of the bones) and malignant lymphomas. it is also used to prevent and treat meningeal leukemia (leukemia infiltration into the central nervous system). it is also used in the treatment of severe rheumatoid arthritis; in the treatment of juvenile idiopathic arthritis, psoriasis and psoriatic arthritis. it is also indicated for the prevention of graft-versus-host disease in allogeneic bone marrow transplantation.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - methotrexate, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - chile, latam (cri, dom, slv, gtm, hnd, nic, pan): methotrexate is a cytotoxic drug used for antineoplastic chemotherapy and in certain nonmalignant conditions. oncological indications: methotrexate is indicated for the treatment of the following solid tumors and hematologic malignancies: ? choriocarcinoma (gestational trophoblastic neoplasm) ? chorioadenoma destruens ? hydatidiform mole ? acute lymphoblastic leukemia ? breast cancer ? cervical cancer ? ovarian carcinoma ? testicular carcinoma ? bladder cancer (locally advanced/metastic) ? epidermoid cancers (squamous cell carcinoma) of head and neck ? mycosis fungoides (cutaneous t cell lymphoma) ? lung cancer ? non-hodgkin?s lymphoma ? meningeal lymphoma ? histiocytic and lymphatic lymphoma, burkitt?s lymphoma ? osteosarcoma ? meningeal leukemia other diseases: ? psoriasis ? rheumatoid arthritis including polyarticular-course juvenile rheumatoid arthritis (jra)

Australien - engelska - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 22.5 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 20 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 17.5 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 15 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - methotrexate, quantity: 12.5 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; water for injections - psoriasis therapy (see warning box): trexject may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis in adults which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.,rheumatoid arthritis therapy (see warning box): management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to, or intolerant of, an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored. steroids may be reduced gradually in patients who respond to methotrexate. combined use of methotrexate with gold or penicillamine, has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.